Click here for slides on this topic


Nateglinide

An oral antihyperglycemic agent of the meglitinide class that is used to treat type 2 diabetes.
The following content matched the glossary term: Nateglinide

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide

Top

Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. ACC Abstracts of the 48th Scientific Session. 2009;32(5):409-418. Hypoglycaemia is an acute complication associated with intensive treatment of patients with diabetes mellitus. This complication poses a major challenge in diabetes management. 

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin

Top

Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009;34(1):13-23. Most antidiabetic agents target only one of several underlying causes of diabetes. The complementary actions of the glinides and the biguanides may give optimal glycemic control in patients with type 2 diabetes mellitus.

Prevention of diabetes & cardiovascular disease in patients w/ impaired glucose tolerance: rationale & design of Nateglinide & Valsartan

Top

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623-632. Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested.

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus

Top

Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005;59:1218-1228. Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin secretion in a transient and glucose-sensitive manner without affecting basal insulin levels.

1 2 Next 

Slide Library Results

Search Results for: Nateglinide Slides Found: 1
Effects of Antidiabetic Agents on Weight